

TECH CENTER 1600/2800
RECEIVED
03 NOV 21 PM 9:10
#26

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of: Wang, et al.

Group Art Unit: 1647

Serial Number: 09/605,577

Examiner: Seharaseyon, J.

Filed: 06/28/2000

Title: Stabilized Interleukin-2

**Response to Notice to Comply with Sequence Submittal Requirements
under 37 CFR 1.821 et sequitur**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22213-1450

Sir:

The following is responsive to the telephonic notification from Examiner Seharaseyon made on November 19th, 2003.

REMARKS


Sequence Listing:

In response to the Examiner's request to provide a copy of the referenced sequence listing in both print and computer readable form (CRF) in the above referenced case, applicants herewith submit both requested items.

Please Note: The content of both the enclosed paper copy of the Sequence Listing and the computer readable copy of the Sequence Listing are the same and include no new matter as required by 37 CFR 1.821 et sequitur.

Should the Office have any questions regarding this communication, please contact applicants' attorney at (510) 705-7725.

Respectfully Submitted,

 11-20-03

John W. Mahoney, Esq.
Patent Counsel
Reg. No. 44,892

Law and Patent Department
Bayer Pharmaceuticals Corporation
800 Dwight Way
P.O. Box 1986
Berkeley California 94701-1986